Clinical and Mycological Spectrum of Chromoblastomycosis: a Case Series


  • Tutty Ariani Dermatology and Venereology Department. Andalas University. Indonesia
  • Yosse Rizal Dermatology and Venereology Department, Achmad Mochtar Regional Hospital, West Sumatera, Indonesia
  • Rahma Ledika Veroci Dermatology and Venereology Department, Achmad Mochtar Regional Hospital, West Sumatera, Indonesia


Chromoblastomycosis, Dematiaceous fungi, Muriform cell


Background: Diagnosis of chromoblastomycosis is often delayed for multiply reasons; poor degree of clinical suspicion or confusion with similar condition due to its polymorphic features and difficulties of confirmed laboratory examination. The case series aims for describing clinical appearance and mycological examination variation of chromoblastomycosis. Cases: We reported four cases of chromoblastomycosis with different type of clinical appearance. Each case appeared with different morphology; verrucous-type, tumor-type, plaque-type and mixed type. All patient had history of contact with soil, multiple trauma and chronic course of disease. Diagnosis of chromoblastomycosis in all cases were confirmed by finding sclerotic bodies in either potassium hydroxide or histopathology examination, the fungal of culture of all cases are suitable of the growth of Fonsecaea pedrosoi. All cases were treated by pulse dose itraconazole 400mg daily for a week every month. Discussion: Chromoblastomycosis is fungal infection caused by pigmented fungi acquired usually by inoculation of the skin as part of occupational or environmental hazards. It is found in immunocompetent host; all cases had no history of comorbidity. As the verrucous-type is the common type, chromoblastomycosis often misdoubt with tuberculosis cutis verrucose, as like our first case. Microscopic detection of sclerotic bodies is important and four cases here confirmed the diagnosis by its finding. Fonsecaea pedrosoi is the most common cause of chromoblastomycosis, detected in the first three cases. Itraconazole and terbinafine are the choice anti-fungal either pulse dose or daily dose.    


Hay RJ. Deep fungal infections. In: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, Orringer JS, editors. Fitzpatrick Dermatology. Ed 9th. New York: McGraw Hill. 2019: 2965-2987.

Yang CS, Chen CB, Lee YY, Yang CH, Chang YC, Chung WH, et al. Chromoblastomycosis in Taiwan : a report of 30 cases and a review of the literature. Medical mycology. 2018;56:395-405.

Feng P and de Hoog GS. Fonsecaea and chromoblastomycosis. In: Mora-montes HM and Lopez-Bezerra LM, editors. Current Progress in Medical Mycology. Springer International Publishing AG. 2017: 333-353.

Queiroz-Telles F, de Hoog S, Santos DWCL, Salgado CG, Vicente VA, Bonifaz A, et al.. Chromoblastomycosis. Clinical Mycrobiology Reviews. 2017;30(1):233-276.

Yahya S et al. Subcutaneous mycosis at the departement of Dermatology and Venereology dr. Cipto Mangunkusumo National Hospital, Jakarta, 1989-2013. j Gen Pro DVI. 2016;1(2):36-43.

Queiroz-Telles F, Esterre P, Perez-Blanco M, Vitales RG, Salgado CG, Bonifaz A. Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment. Medical mycology. 2009;47:3-15.

Queiroz-Telles F and Santos DWCL. Chromoblastomycosis in the clinical practice. Current fungal infection reports. 2012;6:312-319.

Chauhan P, Jindal R, Shirazi N. Dermoscopy of chromoblastomycosis. Indian dermatology online journal. 2019;10:759-760.

Widaty S, Soebono H, Nilasari H, Siswati AS, Rosita C, Hindritiani R, et al. PANDUAN PRAKTEK KLINIS PERDOSKI. 2017. 135–137.

De Brito AC and Bittencourt MJS. Chromoblastomycosis: an etiological, epidemiological, clinical, diagnostic, and treatment update. Anais brasileiros de dermatologia. 2018;93(4):495-506.

Queiroz-Telles F, de C L Santos DW. Challenges in the Therapy of Chromoblastomycosis. Mycopathologia. 2013;175(5–6):477–88.




How to Cite

Ariani T, Rizal Y, Veroci RL. Clinical and Mycological Spectrum of Chromoblastomycosis: a Case Series. J Pak Assoc Dermatol [Internet]. 2023Oct.12 [cited 2023Nov.28];33(4):1750-61. Available from:



Case Reports